National Institute of Environmental Health Sciences, NIH; National Toxicology Program; Solicitation of Comments on Proposed Peer Review of Low-Dose Issues for Endocrine Disruptors

Federal RegisterJan 6, 2000

Ask Donna

What actually matters in this document.

Text

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health service

National Institute of Environmental Health Sciences, NIH;

National Toxicology Program; Solicitation of Comments on Proposed Peer

Review of Low-Dose Issues for Endocrine Disruptors

SUMMARY: NTP is soliciting comments on the planned scope and process

for a proposed peer review of studies bearing on the question of

whether endocrine disruptors may cause effects at doses lower than are

tested using standard toxicological testing procedures. Nominations for

peer reviewers, as well as nominations for studies to be reviewed, are

also being solicited. Results from the peer review will help the U.S.

Environmental Protection Agency (a member agency of the NTP) and, in

particular the EPA's Endocrine Disruptor Screening Program, determine

how to address low-dose questions in endocrine disruptor screening,

testing, and hazard assessment.

Background

The U.S. Environmental Protection Agency (EPA) is implementing an

Endocrine Disruptor Screening Program as required by the Food Quality

Protection Act of 1996 (See 63 FR 71542-71568, Dec. 28, 1998). The EPA

is in the process of choosing appropriate assays to use in this

screening program and is also developing standardized, validated

protocols for these assays. A critical aspect of protocol development

is dose-setting. In recent years, there have been suggestions that

hormonally active agents may cause effects at doses lower than those

normally selected for toxicological testing. A review of the issue can

be found in the National Academy of Science's recently-released report

Hormonally Active Agents in the Environment (NRC [National Research

Council]. 1999. Washington, DC: National Academy Press, pp. 103-111).

The EPA has asked the National Toxicology Program to establish an

independent panel of scientists to review the evidence related to low-

dose effects and consider their implications for the development,

validation, and interpretation of test protocols. If this Panel

concludes that significant effects at low doses occur and that the

standard dose-setting paradigm is inadequate to detect such effects,

the EPA intends to pursue in a separate forum the question of how to

test for such effects, including endpoints to be tested, dose-setting

protocols and appropriate test methods. If the Panel believes the

current data to be inconclusive, it will be asked to describe specific

research that would resolve the ambiguities.

Proposed Scope and Process for the review

A. Scope of the Review

Analysis will focus on interpretation of the major data sets

showing or refuting effects at low doses. ``Low doses'' are defined for

the purposes of discussion as ``doses below the currently accepted No

Observed Adverse Effect Level for that substance''. The intent is to

evaluate the presence or absence of low-dose effects in specific

studies, then evaluate the likelihood and significance of these and/or

other potential low-dose effects to humans.

The main topic to be addressed is evidence for defining the shape

of the dose/response curves for endocrine-active substances in the low-

dos region.

The review is expected to examine all evidence, including such

things as relevant pharmacokinetic and mechanistic information, which

may have a bearing on the low-dose issue. In order to come to

disclosure on the central issue of whether there are sufficient grounds

to change the traditional dose-setting paradigm for endocrine-active

substances, it will not be possible to go into the details of non-

central issues. Issues which may enter the discussion but which are not

the central forcus and will not get exhaustive review include:

--existence of inverted U-shaped dose/response curves as a general

phenomenon in toxicology;

--completeness of the list of endpoints examined in two-generation

toxicity tests;

--definition of ``adversity''.

B. Selection of Studies for Review

Given the breadth of the scope, many studies are likely to be

considered relevant to the discussion. NTP proposes to divide studies

into two categories: those which provide background information and

those which hare critical to the resolution of the issue. Hard copies

of both the background information and critical studies will be

provided to the Panel in advance of the Peer Review Meeting. For the

critical studies, principal investigators will be invited for in-depth

discussions with the Panel, and the data sets from these critical

studies will be subjected to independent analyses by the panel. NTP

anticipates that approximately 10 to 12 studies might be designated

critical.

C. Criteria for Selection of Studies for Review

Studies which provide direct evidence for the presence of effects

related to the endocrine system at doses below the No Observed Adverse

Effect Level will generally be considered critical. Studies which

provide direct evidence against such effects at similar doses for the

same chemical will also generally be considered critical. Studies which

provide direct evidence for endocrine-related effects for chemicals for

which NOAELs have not been established will generally be considered

critical if there is reason to believe that normal procedures for

establishing a NOAEL would set NOAELs at a higher level than those

indicated by the study in question, as long as the difference in

putative NOAELs would be due to dose/response considerations rather

than to definitions of adversity or selection of endpoints for

observation. Studies which provide direct evidence against effects at

similar doses from chemicals for which such claims have been made will

also generally be considered critical.

Pharmacokinetic and mechanistic studies which provide insight into

the plausibility or relevance of effects established in the direct

studies may be either critical or background information depending on

how closely they address low-dose issues.

Studies of other endocrine effects caused by a substance for which

a low-dose endocrine effect is established will be considered

background information unless mechanistic information establishes a

relevant relationship to the low-dose effect.

In general, potency per se, is not a central issue. Studies which

show effects at low doses but whose central issue in setting a NOAEL is

either the definition of adversity or the completeness of the list of

endpoints for which observations are made will not be considered

relevant to the dose/response issues that this peer review will

address.

For background information, well-written reviews will be preferred

over individual studies. Only studies or reviews which have been

published in standard, peer-reviewed scientific journals or books will

be considered.

[[Page 785]]

Critical studies must be accepted for publication in a standard,

peer-reviewed scientific journal or book by April 1, 2000. Studies

presented at scientific meetings but not formally accepted for

publication in a peer-reviewed journal will not be accepted.

Raw data for critical studies must be available for the Panel to

review and analyze. ``Raw data'' includes data on individual laboratory

animals, prior to aggregation by statistical or other methods. Data

reported under Good Laboratory Practices, for example, will generally

be considered ``raw data''.

D. Selection Procedure

An NTP interagency workshop organizing committee will choose the

studies to be considered by the Panel.

NTP recognizes that the date of acceptance for publication cannot

be predicted with accuracy. Similarly, co-operation by principal

investigators to include a study in this review cannot be guaranteed.

For planning purposes, it may become necessary to designate certain

studies as ``likely to be critical'' before April 1 and to treat them

as if they will be examined at the Panel meeting. However, the criteria

will be applied on April 1.

E. Preliminary List of Published Studies To Be Considered by the Low-

Dose Peer Review Panel

The NTP has compiled the attached preliminary list of relevant

studies and invites public comment on the list.

F. Peer Review Panel Members

A panel of 16 to 20 members is anticipated. NTP is soliciting

nominations for the Panel from the public. (See Guidelines for

Submission of Comments below). Kinds of expertise that are likely to be

relevant include reproductive biology (male and female, whole animal

and cellular), endocrinology, pharmacology, statistical data analysis,

and dose/response modeling. Expertise need not be limited to these

areas, nor will these areas necessarily all be included on the Panel.

NTP will try to ensure an appropriate breadth of expertise across the

Panel. If there are particular kinds of expertise that you feel the

Panel should include, please provide a justification in your comments,

especially if the expertise is not covered in the list above.

Nominations should be accompanied by complete contact information,

including name, address, institutional affiliation, telephone number,

and e-mail address. Where possible, a Web page address for research

interests and/or curriculum vitae should be included. To avoid the

potential for candidates being contacted by a large number of

nominators, candidates need not be contacted prior to nomination. NTP

will solicit curricula vitae and interest in participation at an

appropriate time.

G. Criteria for Selection of Panel Members

Expertise in a scientific field relevant to the low-dose issue is

required.

Investigators associated with critical studies will not be

considered for the Panel. Principal investigators (or their designated

co-authors) for critical studies will be asked to present their data

and be available for discussion at the Peer Review Panel meeting, but

will not be asked to be part of the Panel itself.

H. Selection Procedure

Panelists will be chosen after critical studies have been selected.

An NTP interagency organizing committee will select panel members

considering all nominations received from the public as well as

nominations developed internally. All nominees will be contacted for

interest and availability, and curricula vitae will be solicited from

the nominees. Selection will be based on the CVs and accompanying

information such as statements of research interest. Official

invitations to participate will be sent out in approximately April of

2000. The final list of Peer Review panel members will be available to

the public through the Endocrine Disruptor Screening Program's Interent

Web site (http://www.epa.gov/scinpoly/oscpendo/index.htm). Panel

members will be paid as consultants, and candidates will be required to

disclose potential conflicts of interest.

I. Subcommittee Structure

NTP proposes to have Subcommittees of the Peer Review Panel examine

specific aspects of the low-dose issue. Subcommittee topics will be

determined after studies for review have been selected. Topics that may

be appropriate for Subcommittees include:

Data Analysis and Statistics

Pharmacokinetics, Receptor Binding, and Modeling

Effects on Males

Effects on Females

Comments on the appropriateness of having Subcommittees, and of the

specific topics suggested, are welcome.

Approximate Schedule for the Review

A meeting of the Peer Review Panel is tentatively planned for late

July 2000 in the Research Triangle Park, NC area. The entire peer

review panel meeting will be open to the public, limited only by space

available. Details of the meeting location, dates, and times will be

announced at a later time.

In order to meet this deadline, designation of critical studies

will take place in March, with Panel selection to begin in the March/

April time frame.

Between May and late June, the data analysis subcommittee will be

asked to review the data on critical studies. Investigators may be

asked to run analyses of their own data according to the specifications

of the Data Analysis Subcommittee. Approximately four weeks before the

Peer Review, this Subcommittee will have the opportunity to meet with

the investigators by conference call (or, if necessary, at a central

location) to ask questions and obtain additional data that might be

needed in preparation for the Panel meeting. The findings of the Data

Analysis Subcommittee will be made available to the full Peer Review

Panel for discussion at the meeting.

On the first day of the Peer Review Meeting, presentation from

principal investigators for the critical studies will be heard by the

entire Panel. Also, the Data Analysis and Statistics Subcommittee will

present its analysis of the data to the remainder of the Low-Dose

Panel. Principal investigators of the critical studies will be

available for comment.

On the second day, the remaining Subcommittee will meet separately

for discussion. Members of the Data Analysis and Statistics

Subcommittee will be asked to split up between the remaining

subcommittees.

On the third day, the entire Panel will reconvene as a group to

discuss the deliberations of each of the Panels and to integrate the

separate aspects into a report.

Each of the Subcommittees, as well as the full Panel, will produce

a written Report following the meeting, documenting the discussions and

explaining reasons for the scientific judgments made. These reports

will be submitted for publication in an appropriate peer-reviewed

scientific journal. Reports will also be made on the NTP and EPA

(Endocrine Disruptor Screening Program) Web sites.

Public Input Solicited

As described above, the NTP solicits comments on the scope and

process for the review; comments on the NTP preliminary list of studies

for review; the nomination of studies to be considered for review; and

the nomination of peer review panel members. Comments, identified by

docket control number OPPTS-42208A,

[[Page 786]]

must be received on or before February 22, 2000.

Guidelines for Submission of Public Comments

EPA will manage the record-keeping aspects of the Peer Review as

part of the Endocrine Disruptor Screening Program.

You man obtain electronic copies of this document, and certain

other related documents that might be available electronically, from

the EPA Internet Home Page at http://www.epa.gov/. To access this

document, on the Home Page select ``Laws and Regulations'' and then

look up the entry for this document under the ``Federal Register--

Environmental Documents.'' You can also go directly to the Federal

Register listings at http://www.epa.gov/fedrgstr/.

For general information about the Endrocrine Disruptor Screening

Program go to http://www.epa.gov/scipoly/oscpendo/index.htm.

The EPA has established an official record for this action under

docket control number OPPTS-42208A. The official record consists of the

documents specifically referenced in this action, any public comments

received during an applicable comment period, and other information

related to this action. This official record includes the documents

that are physically located in the docket, as well as the documents

that are referenced in those documents. The public version of the

official record does not include any information claimed as CBI. The

public version of the official record, which includes printed, paper

versions of any electronic comments submitted during an applicable

comment period, is available for inspection in the TSCA Nonconfidential

Information Center, North East Mall Rm. B-607, Waterside Mall, 401 M

St., SW, Washington, DC. The Center is open from noon to 4 p.m., Monday

through Friday, excluding legal holidays. The telephone number for the

Center is (202) 260-7099.

You may submit comments through the mail, in person, or

electronically. To ensure proper receipt by EPA, it is imperative that

you identify docket control number OPPTS-42208A in the subject line on

the first page of your response.

1. By mail. Submit your comments to: Document Control Office

(7407), Office of Pollution Prevention and Toxics (OPPT), Environmental

Protection Agency, 401 M St., SW, Washington, DC 20460.

2. In person or by courier. Deliver your comments to: OPPT Document

Control Office (DCO) in East Tower Rm. G-099, Waterside Mall, 401 M St.

SW, Washington, DC. The DCO is open from 8 a.m. to 4 p.m., Monday

through Friday, excluding legal holidays. The telephone number for the

DCO is (202) 260-7093.

3. Electronically. You may submit your comments electronically by

e-mail to: ``[email protected],'' or mail your computer disk to the

address identified above. Do not submit any information that you

consider to be CBI. Electronic comments may be submitted in WordPerfect

6.1/8.0 or as an ASCII file avoiding the use of special characters and

any form of encryption. Comments and data will also be accepted on

standard disks in WordPerfect 6.1/8.0 or ASCII file format. All

comments in electronic form must be identified by docket control number

OPPTS-42208A. Electronic comments may also be filed online at many

Federal Depository Libraries.

Do not submit any information that you consider to be Confidential

Business Information. If you believe that relevant information will be

overlooked because of this restriction, please consult the person

identified under FOR FURTHER INFORMATION CONTACT.

FOR FURTHER INFORMATION CONTACT:

James P. Kariya, Office of Science Coordination and Policy (7203),

Office of Prevention, Pesticides, and Toxic Substances, Environmental

Protection Agency, 401 M St. SW, Washington, DC 20460; telephone

number: (202) 260-2916; e-mail address: [email protected].

Dated: December 28, 1999.

Kenneth Olden,

Director, National Toxicology Program, Department of Health and Human

Services.

Attachment--Preliminary List of Published Studies to Be Considered

by the Low-dose Peer Review Panel

The NTP has compiled a preliminary list of relevant studies. The

public is invited to comment on this list; suggestions for

additions, deletions, and substitutions may be submitted. (See

Section of this FR announcement on Guidelines for Submission of

Public comments.) Submission of a complete copy of the journal

article in which the study and its results are described is

preferred, but a complete reference (authors' names, name of

journal, volume, issue, pages, title, date) will be sufficient if

the complete article cannot be submitted. Include a brief narrative

explaining the reason for each addition, deletion, or substitution.

Raw data need not be submitted at this stage.

Studies which are as yet unpublished but which are expected to

be accepted for publication before April 1, 2000 may be nominated.

An abstract of the study describing highlights of the study

(including species and strain, dosing regimen, duration of study,

number of animals per dose, endpoints evaluated and, if available,

results) must be submitted in order for the Selection Committee to

be able to evaluate the likelihood that the study will be a critical

study. As with published studies, a brief narrative explaining the

significance of as yet unpublished studies should be included.

Studies which are completed but not published are not included

here. This list is being provided as an example of the kinds of

studies that may be appropriate for the Panel to consider. Final

selection of studies has not been made.

Ashby J, Elliott BM. 1997. Reproducibility of endocrine

disruption data. Reg Toxicol Pharmacol 26:94-95.

Ashby J, Tinwell H, Lefevre PA et al. 1997. Normal sexual

development of rats exposed to butyl benzyl phthalate from

conception to weaning. Reg Toxicol Pharmacol 26:102-118.

Boettger-Tong H, Murthy L, Chiapetta C, et al. 1998. A case of a

laboratory animal feed with high estrogenic activity and its impact

on in vivo responses to exogenously administered estrogens. Environ

Health Perspect 106(7):369-373.

Cagen SZ, Waechter JM Jr, Dimond SS, et al. 1999. Normal

reproductive organ development in CF-1 mice following prenatal

exposure to bisphenol A. Toxicol Sci 50:36-44.

Colerangle JB, Roy D. 1997. Profound effects of the weak

environmental estrogen-like chemical bisphenol A on the growth of

the mammary gland of Noble rats. J Steroid Biochem Molec Biol 60(1-

2), 153-160.

Makela SI, Pylkkanen LH, Santti RSS, Adlercreutz H. 1995.

Dietary soybean may be antiestrogenic in male mice. J Nutr 125:437-

445.

Nagel SC, vom Saal FS, Thayer KA, et al. 1997. Relative binding

affinity-serum modified access (RBA-SMA) assay predicts the relative

in vivo bioactivity of the xenoestrogens bisphenol A and

octylphenol. Environ Health Perspect 105:70-76.

Odum J. Pyrah ITG, Foster JR, et al. 1999. Comparative

activities of p-nonylphenol and diethylstilbestrol in Noble rat

mammary gland and uterotrophic assays. Reg Toxicol Pharmacol 29:184-

195.

Portier C, Tritscher A, Kohl M. et al. 1993. Ligand/receptor

binding for 2,3,7,8-TCDD: implications for risk assessment.

Fundamental and Applied Toxicol 20:48-56.

Sharpe RM, Fisher JS, Millar MM, et al. 1995. Gestational and

lactational exposure of rats to xenoestrogens results in reduced

testicular size and sperm production. Environ Health Perspect

103(12): 1136-1143.

Sharp R, Turner KJ, Sumpter JP. 1998. Endocrine disruptors and

testis development [letter]. Environ Health Perspect 106(5): A220-

A221.

Sheehan DM, Willingham E, Gaylor D, et al. 1999. No threshold

dose for estradiol-induced sex reversal of turtle embryos: how

little is too much? Environ Health Perspect 107:155-159.

Spearow J, Doemeny P, Sera R, et al. 1999. Genetic variation is

susceptibility to endocrine disruption by estrogen in mice. Science

285:1259-1261.

vom Saal FS, Quadagno DM, Even MD, et al. 1990. Biology of

Reproduction 43:751-761.

vom Saal FS, Timms BG, Montano MM, et al. 1997. Prostate

enlargement in mice due to

[[Page 787]]

fetal exposure to low doses of estradiol or diethylstilbestrol and

opposite effects at high doses. Proc Natl Acad Sci USA 94:2056-2061.

vom Saal FS, Cooke PS, Buchanan DL, et al. 1998. A

physiologically based approach to the study of bisphenol A and other

estrogenic chemicals on the size of reproductive organs, daily sperm

production, and behavior. Toxicol Indust Hlth 14(__):239-260.

Welshons WV, Nagel SC, Thayer KA, et al. 1999. Low-dose

bioactivity of xenoestrogens in animals: fetal exposure to low doses

of methoxychlor and other xenoestrogens increases adult prostate

size in mice. Toxicol Indust Health 15:12-25.

[FR Doc. 00-228 Filed 1-5-00; 8:45 am]

BILLING CODE 4140-01-M

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.